Children with recessive dystrophic epidermolysis bullosa (RDEB) and their parents reported less pain and itch, better wound healing, and greater participation in daily activities after treatment with Inmune Bio’s Ebstrocel, an experimental stem cell therapy, during the MissionEB trial, according to a new analysis. The findings build on…
Discussion
Inmune Bio has assembled a scientific advisory board to help guide its development of Ebstrocel, a stem cell therapy designed to promote wound healing in people with the fragile skin disease RDEB, fully recessive dystrophic epidermolysis bullosa. The newly formed advisory board will provide Inmune with advice ranging…
Discussion
A U.S.-based biotech company announced that it has reached a “significant” milestone in advancing its experimental stem cell treatment for recessive dystrophic epidermolysis bullosa (RDEB), a rare condition marked by extremely fragile skin. Inmune Bio said it has readied its process for commercial-grade manufacturing of CORDStrom, the stem…
Becoming educated and informed about epidermolysis bullosa is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your EB journey.
There is no cure for EB yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.
